Researchers from Renbio Inc. and Louisiana State University investigated the delivery of plasmid DNA encoding new glucagon-like peptide-1(GLP-1)-based biologics with MYO (Make Your Own) technology as a new therapeutic strategy. This approach ensures the continuous production of GLP-1-based biologics for an extended period, overcoming the need for weekly dosing.